REVIEW ARTICLE [Free Preview]
N Engl J Med 2015; 373:1048-1058September 10, 2015DOI: 10.1056/NEJMra1407304
The pharmacologic and biochemical features of cannabinoids make them candidates for antiseizure medications. At this time, anecdotes have outstripped controlled clinical trials as sources of support for their clinical value.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Dr. Devinsky reports receiving grant support from GW Pharmaceuticals and Novartis and serving on the scientific advisory board of MiaMed; and Dr. Friedman, receiving fees for serving on an advisory board for Marinus Pharmaceuticals and consulting fees from Eisai, Marinus Pharmaceuticals, SK Biopharmaceuticals, Upsher-Smith Laboratories, and Pfizer, all of which were paid to the Epilepsy Study Consortium. No other potential conflict of interest relevant to this article was reported.
Dr. Devinsky reports receiving grant support from GW Pharmaceuticals and Novartis and serving on the scientific advisory board of MiaMed; and Dr. Friedman, receiving fees for serving on an advisory board for Marinus Pharmaceuticals and consulting fees from Eisai, Marinus Pharmaceuticals, SK Biopharmaceuticals, Upsher-Smith Laboratories, and Pfizer, all of which were paid to the Epilepsy Study Consortium. No other potential conflict of interest relevant to this article was reported.
SOURCE INFORMATION
From the Department of Neurology, New York University Langone School of Medicine, New York.
Address reprint requests to Dr. Friedman at the Department of Neurology, NYU Langone School of Medicine, 223 E. 34th St., New York, NY 10016, or at daniel.friedman@nyumc.org.
